Macular translocation is still effective after five years


It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery..

According to data published in the journal Eye it is possible for AMD patients to maintain BCVA for five years after macular translocation surgery.

A team led by Dr K. Takeuchi, Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, assessed the medical records of 61 consecutive patients who experienced macular translocation.

Of the patients included in the study, 35 eyes were treated for AMD and 26 eyes were treated for myopic choroidal neovascularisation (mCNV). Area of the Goldmann visual field (VF) and BCVA were measured before surgery, 12 months after surgery and at the final follow-up.

In the AMD eyes the mean preoperative BCVA was 1.149±0.105 logMAR, improving to 0.69±0.06 logMAR 1 year postoperatively. The BCVA was maintained at 0.633±0.083 logMAR at the final follow-up visit.

In the mCNV eyes the mean preoperative BCVA was 1.083±0.119 logMAR, improving to 0.689±0.121 logMAR one year postoperatively. This was maintained at 0.678±0.142 logMAR at the final follow-up.

For both groups the area of the VF was significantly reduced at 12 months postoperatively and did not change significantly over the following five years.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.